PredicineATLAS
Commercial- Indications
- Cancer
Company intelligence / Profile preview
Predicine has developed proprietary cell-free DNA/RNA-based liquid biopsy technologies enabling minimally invasive molecular diagnosis for treatment selection, therapy monitoring, minimal residual disease assessment, and early cancer detection. Their platforms are validated in global clinical trials with leading biopharma partners. The company regularly presents new data at major scientific meetings like ASCO.
5 more assets in the full pipeline.
Request access →Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Predicine.